Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry
Paloma de Abreu; Sonia Cabrera; Darwin Cordovilla; Lourdes Román; Cristina Brunengo; Patricia Melgarejo; Macarena Soto; Vannia Valinotti; Angelica Amarilla; Belem Acevedo; Alexis Pineda; Evelyn Leiva; Paola Pusineri; Sandra Consani; Mariela Zarza; Clyde Parodi; Zoilo Morel; Roger Rolón; Paola Jara; Raquel Aranda; Laura Martínez; Gabriela Ávila;
Reumatol Clin. 2025;21:
Safety and survival associated with biologic therapies: first report of the Biobadaguay on the Paraguayan-Uruguayan registry of adverse events with biologic therapies
Paloma de Abreu; Gabriela Ávila-Pedretti; Zoilo Morel; María Isabel Acosta; Sonia Cabrera-Villalba; Patricia Melgarejo; Marcos Franco; Pedro Delgadillo; Lourdes Román; Juan Gabriel Elizaur; Ernesto Paredes; Darwin Octavio Cordobilla; Daniel Palleiro; Miguel Albanese; Julio Mazzoleni;
Reumatol Clin. 2020;16P2:396-404
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48